Attorney General Fox Calls for Tamper-Resistant Versions of Generic Prescription Pain Relievers

Attorney General Fox Calls for Tamper-Resistant Versions of Generic Prescription Pain Relievers

Attorney General Tim Fox joined 41 other state and territorial attorneys general in sending a letter today to the U.S. Food and Drug Administration (FDA) urging it to require manufacturers of generic prescription pain relievers to develop tamper-resistant versions of their products.
Prescription drug abuse has reached epidemic levels in many states; requiring abuse-deterrent pain killing prescription drugs (opioids) is a commonsense improvement that provides yet another important tool in the fight against this epidemic.

“We know that nearly eight percent of Montana’s youth between the ages of 12 – 17 reported using prescription pain killers recently for non-medical reasons,” said Attorney General Tim Fox. “Often, these drugs come from the medicine cabinets of family or friends, not from dealers on the street. Asking the FDA to set clear abuse-deterrent guidelines for generic opioids is a step in the right direction to help protect our children from easily obtained and easily abused drugs.”

In their letter, the attorneys general thanked the FDA for its recent efforts to require abuse-deterrent formulations for branded opioid drugs. However, they also urged the FDA to go even further by ensuring that generic opioids, like their branded counterparts, have abuse-deterrent properties.

“Accordingly, the undersigned State Attorneys General respectfully request that the FDA provide clear and fair regulatory standards for the incorporation of abuse-deterrent technologies into generic opioids,” reads the National Association of Attorneys General (NAAG) letter. A copy can be found here: /wp-content/uploads/Final-FDA-Abuse-Deterrent-Letter.pdf .

Attorneys general remain in the national forefront combating prescription abuse by sponsoring prescription drug-take back efforts, spearheading legislative and law enforcement initiatives in their respective jurisdictions, and mandating state level prescription drug monitoring programs.

The 41 attorneys general who signed the NAAG letter are from: Alabama, Arizona, Arkansas, Colorado, Delaware, Florida, Georgia, Guam, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Washington, West Virginia and Wisconsin.

Skip to content